Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 10/20 | 0.41 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.40 |
| ▸ | MMP7 known ✓ | P09237 | 6/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 16/20 | 0.41 |
| ▸ | MMP3 | P08254 | 11/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11130193 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL60916 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL1683449 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5183324 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5086708 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL875996 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL11576013 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL59932 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5088573 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL1011374 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658834-A1 | WET ETCH FORMULATIONS AND RELATED METHODS | Entegris, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-12359113-B2 | Method for dispersing kinetic hydrate inhibitors | CHAMPIONX LLC (US) | 2025-07-15 | — | — | US | claimed |
| US-12295366-B2 | Preservation of personal care compositions | SHARON LABORATORIES LTD. (IL) | 2025-05-13 | — | — | US | claimed |
| US-12194085-B2 | Vaccine for the prevention and treatment of C. difficile infections and the use thereof | INSTYTUT IMMUNOLOGii I TERAPii DOSWiADCZALNEJ LM. LUDWiKA HiRSZFELDA POLSKiEJ AKADEMii NAUK (PL) | 2025-01-14 | — | — | US | claimed |
| CN-119081700-A | Etching solution for selectively removing TiSiN and preparation method thereof | 湖北兴福电子材料股份有限公司 | 2024-12-06 | — | — | CN | claimed |
| US-20240353412-A1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2024-10-24 | — | — | US | claimed |
| WO-2024209069-A1 | HYDROGEN SULPHIDE AND MERCAPTAN SCAVENGING ADDITIVE CONCENTRATE COMPRISING AN OXAZOLIDINE COMPOUND AND A QUATERNARY AMMONIUM SALT | TOTALENERGIES ONETECH (FR) | 2024-10-10 | — | — | WO | claimed |
| EP-4442794-A1 | HYDROGEN SULPHIDE AND MERCAPTAN SCAVENGING ADDITIVE CONCENTRATE COMPRISING AN OXAZOLIDINE COMPOUND AND A QUATERNARY AMMONIUM SALT | TOTALENERGIES ONETECH (FR) | 2024-10-09 | — | — | EP | claimed |
| EP-4428294-A2 | A METHOD FOR PREPARATION OF VIRUCIDAL POLYMER TEXTILE MATERIALS AND VIRUCIDAL FACE MASKS MADE FROM SAID MATERIALS | Jozef Stefan Institute (SI) | 2024-09-11 | — | — | EP | claimed |
| EP-4419619-A1 | SELECTIVE WET ETCH COMPOSITION AND METHOD | Entegris, Inc. (US) | 2024-08-28 | — | — | EP | claimed |
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| EP-1005651-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-06-07 | — | — | EP | claimed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| US-5389300-A | A microbiocidal composition containing a phenolic compound and an iodopropargyl compound | BAYER AKTIENGESELLSCHAFT (DE) | 1995-02-14 | — | — | US | claimed |
| EP-0299191-B1 | MIXTURE OF FUNGICIDALLY ACTIVE AGENTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1992-03-04 | — | — | EP | claimed |
| US-4784910-A | HEAT TREATMENT WITH COPPER SALT, SULFUR REDUCING AGENT AND BASIC NITROGEN SALT | MITSUBISHI RAYON CO., LTD. (JP) | 1988-11-15 | — | — | US | claimed |
| US-4157312-A | QUATERNARY AMMONIUM, METAL CHELATE, SWEETENING | UOP INC. (US) | 1979-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | EXOSC9, EXOSC5, EXOSC4 | MMP1 24/4885HTR2A 1142/4885KCNH2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.